<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03172208</url>
  </required_header>
  <id_info>
    <org_study_id>ALX0681-C103</org_study_id>
    <nct_id>NCT03172208</nct_id>
  </id_info>
  <brief_title>Caplacizumab Single and Multiple Dose Study in Healthy Japanese and White Subjects.</brief_title>
  <official_title>A Phase I Single Center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Caplacizumab in Japanese and White Healthy Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ablynx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ablynx</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective:

      To assess the safety and tolerability of single ascending intravenous (i.v.) doses, a single
      subcutaneous (s.c.) dose of caplacizumab (Part I), and multiple s.c. doses of caplacizumab
      (Part II) in Japanese subjects.

      Secondary objectives:

        -  To compare the pharmacokinetic (PK) and pharmacodynamic (PD) profiles (total vWF:Ag
           concentration levels [vWF:Ag], coagulation factor VIII [FVIII:C], and ristocetin
           cofactor activity [RICO]) after single i.v. or s.c. administration of caplacizumab in
           Japanese and White subjects.

        -  To evaluate the immunogenicity of caplacizumab (anti-drug antibodies [ADA]) in Japanese
           subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 5, 2017</start_date>
  <completion_date type="Actual">October 19, 2017</completion_date>
  <primary_completion_date type="Actual">October 19, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of treatment-emergent adverse events (Safety and Tolerability)</measure>
    <time_frame>From signing of informed consent form until Day 28 (single-dose part) or Day 34 (multiple dose part)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: concentration of caplacizumab in plasma</measure>
    <time_frame>From Day -1 to Day 6 (single dose part) or to Day 12 (multiple dose part)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: concentration of caplacizumab in urine</measure>
    <time_frame>From Day 1 to Day 4 (single dose part) or to Day 8 (multiple dose part)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics as measured by Ristocetin cofactor activity in plasma</measure>
    <time_frame>From Day -1 to Day 6 (single dose part) or to Day 12 (multiple dose part)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics as measured by von Willebrand factor antigen in plasma</measure>
    <time_frame>From screening to Day 6 (single dose part) or to Day 12 (multiple dose part)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics as measured by Factor VIII clotting activity in plasma</measure>
    <time_frame>From Day -1 to Day 6 (single dose part) or to Day 12 (multiple dose part)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity as measured by the concentration of anti-caplacizumab antibodies in serum</measure>
    <time_frame>From screening until Day 28 (single-dose part) or Day 34 (multiple dose part)</time_frame>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Group 1: Japanese - Caplacizumab Dose 1 iv (SD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose (SD) of Caplacizumab Dose 1 administered intravenously (iv) to Japanese participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1: Japanese - Placebo iv (SD)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose (SD) of Placebo administered intravenously (iv) to Japanese participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Japanese - Caplacizumab Dose 2 iv (SD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose (SD) of Caplacizumab Dose 2 administered intravenously (iv) to Japanese participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Japanese - Placebo iv (SD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose (SD) of Placebo administered intravenously (iv) to Japanese participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: White - Caplacizumab Dose 2 iv (SD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose (SD) of Caplacizumab Dose 2 administered intravenously (iv) to White participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: White - Placebo iv (SD)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose (SD) of Placebo administered intravenously (iv) to White participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: Japanese - Caplacizumab Dose 2 sc (SD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose (SD) of Caplacizumab Dose 2 administered subcutaneously (sc) to Japanese participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: Japanese - Placebo sc (SD)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose (SD) of Placebo administered subcutaneously (sc) to Japanese participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: White - Caplacizumab Dose 2 sc (SD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose (SD) of Caplacizumab Dose 2 administered subcutaneously (sc) to White participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: White - Placebo sc (SD)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose (SD) Placebo administered subcutaneously (sc) to White participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: Japanese - Caplacizumab Dose 2 sc (MD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses (MD) of Caplacizumab Dose 2 administered subcutaneously (sc) to Japanese participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: Japanese - Placebo sc (MD)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple doses (MD) of Placebo administered subcutaneously (sc) to Japanese participants</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Caplacizumab Dose 1 iv (single-dose)</intervention_name>
    <description>Single intravenous (iv) administration of Caplacizumab Dose 1</description>
    <arm_group_label>Group 1: Japanese - Caplacizumab Dose 1 iv (SD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Caplacizumab Dose 2 iv (single-dose)</intervention_name>
    <description>Single intravenous (iv) administration of Caplacizumab Dose 2</description>
    <arm_group_label>Group 2: Japanese - Caplacizumab Dose 2 iv (SD)</arm_group_label>
    <arm_group_label>Group 2: White - Caplacizumab Dose 2 iv (SD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Caplacizumab Dose 2 sc (single-dose)</intervention_name>
    <description>Single subcutaneous (sc) administration of Caplacizumab Dose 2</description>
    <arm_group_label>Group 3: Japanese - Caplacizumab Dose 2 sc (SD)</arm_group_label>
    <arm_group_label>Group 3: White - Caplacizumab Dose 2 sc (SD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Caplacizumab Dose 2 sc (multiple-dose)</intervention_name>
    <description>Once daily subcutaneous (sc) administration of Caplacizumab Dose 2 during 7 consecutive days</description>
    <arm_group_label>Group 4: Japanese - Caplacizumab Dose 2 sc (MD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo iv (single-dose)</intervention_name>
    <description>Single intravenous (iv) administration of Placebo</description>
    <arm_group_label>Group 1: Japanese - Placebo iv (SD)</arm_group_label>
    <arm_group_label>Group 2: Japanese - Placebo iv (SD)</arm_group_label>
    <arm_group_label>Group 2: White - Placebo iv (SD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo sc (single-dose)</intervention_name>
    <description>Single subcutaneous (sc) administration of Placebo</description>
    <arm_group_label>Group 3: Japanese - Placebo sc (SD)</arm_group_label>
    <arm_group_label>Group 3: White - Placebo sc (SD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo sc (multiple-dose)</intervention_name>
    <description>Once daily subcutaneous (sc) administration of Placebo during 7 consecutive days</description>
    <arm_group_label>Group 4: Japanese - Placebo sc (MD)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI between ≥18 kg/m² and &lt;30 kg/m² at time of screening

          -  Body weight between ≥45 kg and &lt;100 kg

          -  Baseline vWF:Ag between ≥60% and &lt;170% (0.6-1.7 IU/mL)

        Exclusion Criteria:

          -  History of and/or any sign or symptom indicating current abnormal hemostasis or blood
             dyscrasia, including but not limited to thrombocytopenia, thrombocytopathy,
             thromboasthenia, hemophilia, von Willebrand's disease, vascular purpura, bleeding gums
             and/or frequent nose bleeding, easy/spontaneous bruises, meno- or metrorrhagia,
             history of gastrointestinal bleeding or excessive bleeding after minor injury such as
             shaving.

          -  Family history of congenital vascular malformation (e.g., Marfan's Syndrome) and/or
             bleeding disorder (e.g., hemophilia, von Willebrand's disease, Christmas disease)

          -  Any surgical intervention (including tooth extraction) or trauma within the 4 weeks
             preceding screening for the study or any planned surgical intervention during the
             participation in the study

          -  Treatment with vitamin K, direct oral anticoagulant (DOAC), warfarin, high dose
             heparin within 2 weeks before screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ablynx Clinical Department</last_name>
    <role>Study Director</role>
    <affiliation>Ablynx</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2017</study_first_submitted>
  <study_first_submitted_qc>May 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2017</study_first_posted>
  <last_update_submitted>November 9, 2017</last_update_submitted>
  <last_update_submitted_qc>November 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

